Bortezomib and vorinostat in refractory acute myelogenous leukemia and high-risk myelodysplastic syndromes: Produces stable disease but at the cost of high toxicity

Leukemia

Volumn 27, Issue 8, 2013, Pages 1789-1791

  Warlick, E D ^a   Cao, Q ^b   Miller, J ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLOGENEIC STEM CELL TRANSPLANTATION; ANOREXIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER SURVIVAL; CLINICAL ARTICLE; COMORBIDITY; CONSTIPATION; CREATININE BLOOD LEVEL; CYTOGENETICS; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; HEART ARREST; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; HYPERNATREMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; KARNOFSKY PERFORMANCE STATUS; LETTER; LEUKEMIA REMISSION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; QT PROLONGATION; REFRACTORY PERIOD; SEPSIS; SIDE EFFECT; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; PYRAZINES; TREATMENT OUTCOME;

EID: 84881475996     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.61     Document Type: Letter

References (15)

1. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001; 98: 2301-2307.
2. Guzman ML, Swiderski CF, Howard DS, Grimes BA, Rossi RA, Szilvassy SJ et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA 2002; 99: 16220-16225. (Pubitemid 35462776)
3. Riccioni R, Senese M, Diverio D, Riti V, Buffolino S, Mariani G et al. M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis. Br J Haematol 2007; 139: 194-205. (Pubitemid 47493077)
4. Minderman H, Zhou Y, O'Loughlin KL, Baer MR. Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status. Cancer Chemother Pharmacol 2007; 60: 245-255. (Pubitemid 46742540)
5. Cortes J, Thomas D, Koller C, Giles F, Estey E, Faderl S et al. Phase I study of borte-zomib in refractory or relapsed acute leukemias. Clin Cancer Res 2004; 10: 3371-3376. (Pubitemid 38685442)
6. Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kurdik FJ, Allred T et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105: 3058-3065.
7. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG et al. Phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced leukemias and myelodys-plastic syndromes. Blood 2008; 111: 1060-1066. (Pubitemid 351213383)
8. Gojo I, Jiemjit A, Trepel JB, Sparreboom A, Figg WD, Rollins S et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007; 109: 2781-2790. (Pubitemid 46482071)
9. Heider U, von Metzler I, Kaiser M, Rosche M, Sterz J, Rotzer S et al. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur J Haematol 2008; 80: 133-142.
10. Emanuele S, Lauricella M, Carlisi D, Vassallo B, D'Anneo A, Di Fazio P et al. SAHA induces apoptosis in hepatoma cells and synergistically interacts with the pro-teasome inhibitor Bortezomib. Apoptosis 2007; 12: 1327-1338. (Pubitemid 46890392)
11. Holkova B, Perkins EB, Sokol L, Richards KL, Parekh S, Elstrom R et al. A Phase II trial of bortezomib and vorinostat in mantle cell lymphoma and diffuse large b-cell lymphoma. Blood 2011; 118: ASH abstract 779.
12. Weber DM, Graef T, Hussein M, Sobecks RM, Schiller GJ, Lupinacci L et al. Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 2012; 12: 319-324.
13. Friday BB, Anderson SK, Buckner J, Yu C, Giannini C, Geoffroy F et al. Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer group study. Neuro Oncol 2012; 14: 215-221.
14. Dimopoulos MA, Jagannath S, Yoon S, Siegel D, Lonial S. Vantage 088: vorinostat in combination with bortezomib in patients with refractory/relapsed multiple myeloma: results of a global, randomized phase 3 trial. Blood 2011; 118: ASH abstract 811.
15. Siegel D, Dimonopoulos, Yoon S, Laubach J, Kaufman J. Vantage 095: vorinostat in combination with bortezomib in salvage multiple myeloma patients: final study results of a global phase 2b trial. Blood 2011; 118: ASH abstract 480.